Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

被引：77

作者：

Stuver, Robert ^{[1
]}

Shah, Gunjan L. ^{[2
]}

Korde, Neha S. ^{[3
]}

Roeker, Lindsey E. ^{[4
]}

Mato, Anthony R. ^{[4
]}

Batlevi, Connie L. ^{[1
]}

Chung, David J. ^{[2
]}

Doddi, Sital ^{[5
]}

Falchi, Lorenzo ^{[1
]}

Gyurkocza, Boglarka ^{[2
]}

Hamilton, Audrey ^{[1
]}

Lin, Ya-Hui ^{[5
]}

Jakubowski, Ann A. ^{[2
]}

Joffe, Erel ^{[1
]}

Landau, Heather L. ^{[2
]}

Lin, Richard J. ^{[2
]}

Mailankody, Sham ^{[3
]}

Palomba, M. Lia ^{[1
]}

Park, Jae H. ^{[4
]}

Perales, Miguel-Angel ^{[2
]}

Ponce, Doris M. ^{[2
]}

V. Ramanathan, Lakshmi ^{[5
]}

Salles, Gilles A. ^{[1
]}

Scordo, Michael ^{[2
]}

Seo, Susan K. ^{[6
]}

Shah, Urvi A. ^{[3
]}

Stein, Eytan M. ^{[4
]}

Straus, David ^{[1
]}

Usmani, Saad Z. ^{[3
]}

Young, James W. ^{[2
]}

Zelenetz, Andrew D. ^{[1
]}

Noy, Ariela ^{[1
]}

Vardhana, Santosha A. ^{[1
,7
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA

[6] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, Div Subspecialty Med, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER CELL | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1016/j.ccell.2022.05.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：590 / 591

页数：2

共 50 条

[31] Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients
Sanayei, Ava M.
Montalvan, Adriana
Faria, Isabella
Ochalla, Julia
Pavlakis, Martha
Blair, Barbra M.
Alonso, Carolyn D.
Curry, Michael
Saberi, Behnam
TRANSPLANTATION PROCEEDINGS, 2023, 55 (08) : 1784 - 1792
[32] Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis
Duminuco, Andrea
Nardo, Antonella
Orofino, Alessandra
Giunta, Giuliana
Conticello, Concetta
Del Fabro, Vittorio
Figuera, Amalia
Chiarenza, Annalisa
Milone, Giuseppe
Leotta, Salvatore
Cupri, Alessandra
Parisi, Marina
Mauro, Elisa
Vetro, Calogero
Di Raimondo, Francesco
Romano, Alessandra
Palumbo, Giuseppe A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S446 - S447
[33] COST-EFFECTIVENESS OF AZD7442 (TIXAGEVIMAB AND CILGAVIMAB) FOR PRE-EXPOSURE PROPHYLAXIS AGAINST COVID-19 IN THE IMMUNOCOMPROMISED POPULATION
Sutton, K.
Miller, P.
Branscombe, N.
Mittal, M.
Browne, C.
Arnetorp, S.
Henry, T.
Breslin, K.
Bungey, G.
Quint, J.
Montgomery, H.
VALUE IN HEALTH, 2022, 25 (12) : S168 - S168
[34] Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity
Johnson, Sarah
McDonnell, John C.
Fernandez, James M.
JOURNAL OF CLINICAL IMMUNOLOGY, 2023, 43 (05) : 865 - 868
[35] Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity
Sarah Johnson
John C. McDonnell
James M. Fernandez
Journal of Clinical Immunology, 2023, 43 (5) : 865 - 868
[36] Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia
Benjamini, Ohad
Tadmor, Tamar
Avigdor, Abraham
Gershon, Rotem
Kliker, Limor
Fares, Florin
Atari, Nofar
Laevsky, Ilana
Abdelkader, Bayan
Hod, Tammy
Golan-Shany, Orit
Mandelboim, Michal
Rahav, Galia
ACTA HAEMATOLOGICA, 2024, 147 (06) : 634 - 645
[37] Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
Forte-Soto, Pablo
Albayaty, Muna
Brooks, Dennis
Arends, Rosalinda H.
Tillinghast, John
Aksyuk, Anastasia A.
Bouquet, Jerome
Chen, Cecil
Gebre, Asfiha
Kubiak, Robert J.
Reddy, Venkatesh Pilla
Seegobin, Seth
Streicher, Katie
Templeton, Alison
Esser, Mark T.
JOURNAL OF INFECTIOUS DISEASES, 2023, 227 (10): : 1153 - 1163
[38] Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period
Hayek, Samah
Levy, Joseph
Shaham, Galit
Dagan, Noa
Serby, Danielle
Duskin-Bitan, Hadar
Dube, Sabada
Ferreira, Catia
Livnat, Idit
Talarico, Carla
Taylor, Sylvia
Venkatesan, Sudhir
Yarden, Adva
Balicer, Ran D.
Netzer, Doron
Peretz, Alon
INFECTIOUS DISEASES AND THERAPY, 2025, 14 (02) : 433 - 445
[39] Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study
Assanto, Giovanni Manfredi
Totaro, Matteo
Poggiali, Rebecca
Delli Paoli, Adele
Annechini, Giorgia
D'Elia, Gianna Maria
Aji, Francesco
Petrucci, Luigi
Fazio, Francesca
Del Giudice, Ilaria
Martelli, Maurizio
Micozzi, Alessandra
Gentile, Giuseppe
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2023, 15 (01)
[40] Efficacy and Safety of Tixagevimab-Cilgavimab (Evusheld or AZD7442) As Pre-Exposure Prophylaxis for COVID-19 Among Allogeneic Hematopoietic Stem Cell Transplant Recipients
Do, Quan
Bahaj, Waled
Chandler, Natasha
Chao, Ju-Hsien
Emmons, Robert V. B.
Hegazi, Mohamed
BLOOD, 2023, 142

← 1 2 3 4 5 →